Clinical, Biochemical and Epigenetic Profile of Pediatric Behçet Disease (NCT07375940) | Clinical Trial Compass
RecruitingNot Applicable
Clinical, Biochemical and Epigenetic Profile of Pediatric Behçet Disease
Italy, United Kingdom90 participantsStarted 2026-01-12
Plain-language summary
Behçet disease (BD) is a chronic multisystem inflammatory disorder with a relapsing-remitting course. Pediatric-onset BD is rare and characterized by marked clinical heterogeneity, frequent incomplete presentation at disease onset, and limited availability of pediatric-specific outcome measures and biomarkers.
This prospective multicenter study aims to comprehensively characterize the clinical, biochemical, genetic, and epigenetic profiles of pediatric patients with Behçet disease and to compare them with adult BD patients and healthy pediatric controls.
The study focuses on the identification of disease-associated cytokine patterns, circulating microRNA profiles, DNA methylation signatures, and genetic variants associated with monogenic autoinflammatory diseases presenting with a Behçet-like phenotype.
By integrating clinical data with multi-omic analyses, this study seeks to identify biologically and clinically meaningful patient subgroups, improve disease stratification, and explore potential biomarkers of disease activity and remission in pediatric Behçet disease.
Who can participate
Age range6 Months – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Cases Inclusion Criteria :
* BD diagnosis according to at least one of the three sets of classification criteria \[International Criteria for Behçet's Disease (ICBD), International Study Group (ISG) and Pediatric Behçet's disease criteria PEDBD)\];
* Age 6 months to 70 years old.
* Written informed consent from appropriate legal representative(s), and assent from patients who have not reached the age of consent.
Cases Exclusion Criteria:
* Patients who do not meet the BD criteria OR
* Patients for whom an alternative diagnosis was not investigated and/or excluded OR
* Absence of a written informed consent.
Healthy pediatric controls:
* Patients evaluated at the Meyer Children's Hospital IRCCS Rheumatology Outpatient Clinic who are scheduled to undergo routine hematochemical tests, not for suspected inflammatory or autoimmune conditions.
* Age \< 18 years, matched 1:1 by age and sex with the pediatric Behçet disease (BD) cohort.
* Absence of recent or ongoing inflammatory conditions, verified through structured medical history and physical examination.
* No clinical signs suggestive of chronic autoinflammatory or autoimmune diseases at physical examination .
* No recent prolonged use (more than 7 consecutive days within the past 4 weeks) of anti-inflammatory, glucocorticoids, immunomodulatory, therapies or antibiotics.
* Written informed consent from the legal guardian(s) and assent from minors when appropriate.
Healthy Controls Exclusion Criteria
* Diagnosis of acute o…
What they're measuring
1
Quantitative biomarker profiles in Behçet disease